Clinical and prognostic value of determining the level of neopterin in patients with chronic heart failure with preserved ejection fraction
https://doi.org/10.21886/2219-8075-2018-9-3-84-89
Abstract
Objective: to analyze the level of neopterin in patients with chronic heart failure (CHF) with a preserved fraction ejection fraction depending on the stage of the disease. Materials and methods: were examined 148 patients with CHF with preserved ejection fraction (50% and >) and 30 as a control group. Patients with CHF were divided into groups depending on the stage of CHF (from I to III). The level of neopterine was determined by the method of enzyme immunoassay in blood plasma. Results: in patients with CHF with preserved ejection fraction there was a tendency to increase the level of neopterin from stage I to stage III compared to the control group. In the group of patients with CHF IIB+III the level of neoplasm was statistically slightly lower compared to patients of stage I and IIA, but statistically signifi cantly higher than in the control group. Conclusion: it was revealed the change in the level of neopterin in patients with CHS with retained ejection fraction depending on the stage of the disease.
About the Authors
O. S. Polunina
Astrakhan State Medical University, Astrakhan
Russian Federation
Competing Interests: Авторы заявляют об отсутствии конфликта интересов.
Russian Federation
Olga S. Polunina, Dr. Sci. (Med.), Professor, Head of Department
Competing Interests: Авторы заявляют об отсутствии конфликта интересов.
L. P. Voronina
Astrakhan State Medical University, Astrakhan
Russian Federation
Competing Interests: Авторы заявляют об отсутствии конфликта интересов.
Russian Federation
Lyudmila P. Voronina, Dr. Sci. (Med.), Professor of Department
Competing Interests: Авторы заявляют об отсутствии конфликта интересов.
I. V. Sevostyanova
Astrakhan State Medical University, Astrakhan
Russian Federation
Irina V. Sevostyanova, Cand. Sci. (Med.), Assistant
Competing Interests: Авторы заявляют об отсутствии конфликта интересов.
Russian Federation
Irina V. Sevostyanova, Cand. Sci. (Med.), Assistant
Competing Interests: Авторы заявляют об отсутствии конфликта интересов.
E. A. Polunina
Astrakhan State Medical University, Astrakhan
Russian Federation
Competing Interests: Авторы заявляют об отсутствии конфликта интересов.
Russian Federation
Polunina A. Ekaterina, Cand. Sci. (Med.), Senior researcher of the research Institute of the regional infectious pathology
Competing Interests: Авторы заявляют об отсутствии конфликта интересов.
References
1. Garganeeva AA, Bauer VA, Borel’ KN. Th e pandemic of the XXI century: chronic heart failure – a burden of modern society. epidemiological aspects (literature review). Siberian medical journal. 2014;29(3):8 -12. (in Russ.)
2. Bazaeva EV, Myasnikov RP, Metel’skaya VA, Boitsov SA. Diagnostic value ofbiological markers in chronic heart failure with preserved ejection fraction of the leftventricle. Journal Of Heart Failure.2015;16(1):43-51. (in Russ.)
3. Tsoi LG. Cytokines and chronic heart failure. Bulletin of the Kyrgyz-Russian Slavic University. 2017;17(7):72-75. (in Russ.)
4. Kovaleva ON. Correction of cytokine aggression in heart failure: theoretical background and practical realities. Heart failure. 2011;(2):93-100. (in Russ.)
5. Rebrov AP, SazhinaEYu, Toma MI. Endothelial dysfunction and peculiarities of changes in cytokine and C-reactive protein levels in patients with chronic heart failure. Russian journal of cardiology.2005;(2): 26-31. (in Russ.)
6. Polunina EA, Sevost’yanova IV, Voronina LP, Polunina OS, Mitrokhina DS. The relationship between enhanced level fractalkine and dysfunction of the vascular endothelium in chronic heart failure. Astrakhan medical journal. 2014;9(2):69-74. (in Russ.)
7. Osipova OA, Plaksina KG, Komisov AA, Godlevskaya OA. Pathogenetic mechanisms of participation of myocardial intercellular matrix in heart remodeling in patients with chronic heart failure. Scientific sheets of Belgorod state University. Series: Medicine. Pharmacy. 2015;32(22):18-25. (in Russ.)
8. Baranov AP, Strutynskii AV, Panchenko LF, Davydov BV, Stepanova GP, et al. Features of autonomic dysfunction, system activity of Pro-inflammatory cytokines and oxidative stress in patients with chronic heart failure and depressive disorders. Pathogenesis. 2016;14(2):66-70. (in Russ.)
9. Kravchenko AYa, Chernyaeva YuM. Th e role of cytokines in the development and course of heart failure. Clinical medicine. 2013;(10):11-16.
10. Strutynskii AV, Gorbacheva EV, Baranov AP, Buzin AG, Trishina VV, et al. Th e importance of biomarkers in the diagnosis and evaluation of prognosis of patients with cardiovascular and pulmonary diseases. The Russian medical journal.2015;16(2):73-80. (in Russ.)
11. Esmedlyaeva DS, Alekseeva NP, Pavlova MV, D’yakova ME, Kiryukhina LD, Perova TL. Blood serum neopterin as an integral indicator of process activity in patients with infiltrative pulmonary tuberculosis. Medical Alliance. 2016;(2):20-25. (in Russ.)
12. Saidov MZ, Alieva MG, Abdullaev AA, KhasaevASh, Adueva SM. Prognostic value of cardiospecific changes in the immune system in clinical outcomes of acute coronary syndrome. Immunologiya.2015;(2):110-115. (in Russ.)
13. Demochko EA, Minushkina LO. Th e importance of biomarkers in the diagnosis and evaluation of prognosis of patients with cardiovascular and pulmonary diseases. The Russian medical journal. 2014;(6): 43-47. (in Russ.)
14. Mareev VYu, Fomin IV, Ageev FT, Arutyunov GP, Begrambekova YuL, et al. Clinical guidelines congestive heart failure (CHF). Journal Of Cardiac Failure.2017;18(1):3–40 (in Russ.) doi: 10.18087/rhfj.2017.1.234
15. Yamamoto E, Hirata Y, Tokitsu T, Kusaka H, Tabata N, et al. The clinical significance of plasma neopterin in heart failure with preserved leftventricular ejection fraction. ESC Heart Fail. 2016;1:53-59. doi: 10.1002/ehf2.12070
16. Berg KS, Stenseth R, Pleym H, Wahba A, Videm V. Neopterin predicts cardiac dysfunction following cardiac surgery. Interact CardiovascTh orac Surg. 2015;21(5):598-603. doi: 10.1093/icvts/ivv219
17. Shao Z, Zhang R, Shrestha K, Borowski AG, Schuster A, et al. Usefulness of elevated urine neopterinlevels in assessing cardiac dysfunction and exercise ventilation ineffi ciency in patientswithchronicsystolic heart failure. Am J Cardiol. 2014;113(11):1839-1843. doi: 10.1016/j.amjcard.2014.03.016
18. Caruso R, De Chiara B, Campolo J, Verde A, Musca F, et al. Neopterinlevels are independently associated with cardiac remodeling in patients with chronic heart failure. Clinical Biochemistry. 2013;46(1-2):94-98.
19. Ozerova EA, Knyazeva LI, Goryainov II, Knyazeva LA, Meshcherina EM, Meshcherina NS. Dynamics of the content of TNF-α and neopterin in patients with chronic cardiac insuffi ciency on the background of treatment. Fundamental study.2005;(6):99. (in Russ.)
Review
For citations:
Polunina O.S., Voronina L.P., Sevostyanova I.V., Polunina E.A. Clinical and prognostic value of determining the level of neopterin in patients with chronic heart failure with preserved ejection fraction. Medical Herald of the South of Russia. 2018;9(3):84-89. (In Russ.) https://doi.org/10.21886/2219-8075-2018-9-3-84-89
Views:
783
Email this article 